Ioanoviciu Alexandra, Antony Smitha, Pommier Yves, Staker Bart L, Stewart Lance, Cushman Mark
Department of Medicinal Chemistry and Molecular Pharmacology and the Purdue Cancer Center, School of Pharmacy and Pharmaceutical Sciences, Purdue University, West Lafayette, Indiana 47907, USA.
J Med Chem. 2005 Jul 28;48(15):4803-14. doi: 10.1021/jm050076b.
Several norindenoisoquinolines substituted with methoxy or methylenedioxy groups have been prepared and their anticancer properties evaluated in cancer cell cultures and in topoisomerase I inhibition assays. 2,3-Dimethoxy-8,9-methylenedioxy-11H-indeno[1,2-c]isoquinoline hydrochloride (14) is a strong topoisomerase I inhibitor and also displays very high cytotoxicity in the NCI cancer cell culture screen (mean graph midpoint of 50 nM). The X-ray crystal structure of norindenoisoquinoline 14 in complex with topoisomerase I and DNA has been solved, providing insight into the structure-activity relationships within this class of new anticancer agents. The number and position of the norindenoisoquinoline substituents have a significant influence on biological activity and demonstrate that substitution on the nitrogen atom is not an absolute requirement for the antitumor effect of the indenoisoquinolines. Removal of the 11-keto group from the lead compound 1 and replacement of the N-alkyllactam with an unsubstituted pyridine ring causes the indenoisoquinoline ring system to flip over in the DNA-enzyme-inhibitor ternary complex. This allows the nitrogen atom to assume the hydrogen bond acceptor role of the 11-keto group, resulting in hydrogen bonding to Arg364.
已制备了几种用甲氧基或亚甲二氧基取代的降茚并异喹啉,并在癌细胞培养物和拓扑异构酶I抑制试验中评估了它们的抗癌特性。2,3-二甲氧基-8,9-亚甲二氧基-11H-茚并[1,2-c]异喹啉盐酸盐(14)是一种强效拓扑异构酶I抑制剂,并且在NCI癌细胞培养筛选中也表现出非常高的细胞毒性(平均图形中点为50 nM)。已解析了降茚并异喹啉14与拓扑异构酶I和DNA复合物的X射线晶体结构,为这类新型抗癌药物的构效关系提供了深入了解。降茚并异喹啉取代基的数量和位置对生物活性有显著影响,并表明氮原子上的取代对于茚并异喹啉的抗肿瘤作用不是绝对必需的。从先导化合物1中去除11-酮基并用未取代的吡啶环取代N-烷基内酰胺会导致茚并异喹啉环系统在DNA-酶-抑制剂三元复合物中翻转。这使得氮原子能够承担11-酮基的氢键受体作用,从而与Arg364形成氢键。